Assessment of Neoadjuvant Treatment Response Using Automated Breast Ultrasound in Breast Cancer

Xiaozhi Dang 1, Xin Zhang 2, Yi Gao 2, Hongping Song 1

1Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi’an, China
2School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, China

ABSTRACT

Breast imaging techniques are used to assess the tumor response to neoadjuvant treatment (NAT), which is increasingly one of the preferred therapeutic options and increases the rate of breast conservation for breast cancer. Herein, we report a case in which a woman was diagnosed with invasive ductal carcinoma in the left breast and received NAT before surgery. Automated breast ultrasound (AB US) was regularly performed before and during the NAT to evaluate the tumor response to NAT by measuring diameter changes and volume reductions of the tumor. Images showed that the tumor size was significantly reduced and disappeared after 7 cycles of NAT, except for macrocalcification. Postoperative histopathological examination confirmed that there were no residual tumor cells. We found that AB US overcame the limitations of handheld US, such as operator dependence, poor reproducibility and limited field of view, and can be an alternative modality to assess the tumor response of NAT in the absence of magnetic resonance imaging (MRI) instruments.

Keywords: Breast Neoplasms; Neoadjuvant Therapy; Treatment Outcome; Ultrasonography

INTRODUCTION

Neoadjuvant treatment (NAT) is widely used in breast cancer treatment to induce tumor shrinkage and increase the rate of breast conservation [1,2]. Tumor size regularly measured by mammography, ultrasound (US) and magnetic resonance imaging (MRI) during NAT and before surgery is necessary to evaluate the tumor response of NAT and is an important consideration in surgical planning [3,4]. We report a case in which breast cancer response was assessed during NAT with automated breast ultrasound (AB US).

CASE REPORT

A 53-year-old woman accidentally touched a mass in her left breast. Breast ultrasound indicated a 4.5 cm irregular mass, with enlarged ipsilateral axillary lymph nodes. Breast Imaging Reporting and Data System (BI-RADS) category 5 was assigned. The histopathological examination after core needle biopsy revealed an invasive ductal carcinoma.
of the estrogen receptor-positive and human epidermal growth factor 2-positive subtype and positive axillary lymph nodes. After a multidisciplinary discussion, the patient received NAT, which was an EC-THP regimen (4 cycles of epirubicin/cyclophosphamide followed by 4 cycles of docetaxel/trastuzumab/pertuzumab), before surgery. AB US (Invenia ABUS 2.0, Automated Breast Ultrasound System; GE Healthcare, Wuxi, China) was performed before NAT on August 11, 2020; after 2 cycles on October 09, 2020; after 5 cycles on December 11, 2020; and after 7 cycles on February 10, 2021 to assess the tumor response. Images showed that the tumor size was significantly reduced and disappeared after 7 cycles of NAT, except for macrocalcification (Figure 1). The tumor 3D images from AB US reconstructed by 3D Slicer (Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA) also showed reductions in tumor volume (Figure 2, Supplementary Video 1). After 8 cycles of NAT, the patient underwent surgery. Postoperative histopathological examination confirmed that there were no residual tumor cells in the breast and axillary lymph nodes, indicating pathological complete response (pCR).

DISCUSSION

Imaging techniques, such as mammography, US, MRI and positron emission tomography (PET), are important approaches for evaluating residual tumor size during NAT for breast cancer, [3,5]. By assessing the tumor response, these techniques not only guide the selection of treatment regimens and reduce the unnecessary toxicity of ineffective regimens but also assist clinical decision-making about performing conservative breast surgery [4].

Changes in tumor diameter are an important criterion for response evaluation in solid tumors [6], and volume reduction has a stronger association with recurrence-free survival than other prognostic indicators [7]. MRI is the most accurate imaging modality for predicting residual tumor size during NAT [8,9]. However, MRI is time-consuming, expensive and requires the injection of a contrast agent, which hampers MRI popularity in developing countries. US is the most popular modality to assess tumor response and a reasonable alternative strategy for predicting residual lesions with NAT [10]. It was reported that MRI estimated the residual tumor size with < 10-mm discordance in 54% of patients, overestimated the size in 28% and underestimated the size in 18%, while US was reported as 63%, 20% and 17%, respectively. US was at least as good as breast MRJ in providing information on residual tumor size following neoadjuvant chemotherapy [11].

AB US, which was initially developed for breast cancer screening, acquires standardized US images of the whole breast with a 15.4 cm wide imaging field, overcoming the limitation of small fields of view and addressing the operator dependence associated with handheld ultrasound (HH US) [12,13]. In this case, AB US was performed before and during the NAT. Reductions in tumor size with a concentric shrinkage pattern were shown in grayscale images. Reconstructed 3D images of tumors and automated or semiautomated volumetric measurements were also available with 3D Slicer, which provided intuitive changes in tumor size. Calcification in AB US images remained despite pCR, which is consistent with reports that calcification appearance does not clearly change after NAT, the persistence of calcifications does not necessarily indicate residual disease, and calcification patterns are not related to the pCR rate [14,15].
Figure 1. Coronal (left) and transverse (right) automated breast US images in a 53-year-old woman with invasive ductal carcinoma of the estrogen receptor-positive and human epidermal growth factor 2-positive subtypes before and during NAT, with macrocalcification in the mass (arrows) as a landmark. (A) Baseline images obtained before NAT showed an irregular mass in the left upper outer breast. The maximal diameter of the mass was 4.5 cm. (B) On images obtained after 2 cycles of NAT, the mass showed a concentric shrinkage pattern. The maximal diameter of the residual mass was 3.1 cm (31% reduction of the initial tumor diameter). (C) On images obtained after 5 cycles of NAT, the maximal diameter of the residual mass was 1.1 cm (76% reduction of the initial tumor diameter). (D) On images obtained after 7 cycles of NAT, the mass disappeared except for macrocalcification. Note: To observe the mass on the same transverse plane to ensure a precise comparison in different cycles, we chose the macrocalcification in the mass as a landmark. The transverse images in (A) and (B) do not show the maximal diameter of the mass. The yellow point indicates the nipple.

NAT = neoadjuvant treatment; LLAT= left lateral.
In conclusion, AB US, which is less time-consuming and less expensive than MRI and does not require the injection of a contrast agent, can be an alternative modality for assessing the tumor response to NAT in low- and middle-income countries. AB US not only overcomes the limitations of HH US but also allows the reconstruction of 3D images and volumetric measurements of tumor size.

**SUPPLEMENTARY MATERIAL**

**Supplementary Video 1**

The movie produced by 3D Slicer shows reductions in tumor volume during NAT based on automated breast US images. Upper left: transverse plane; Lower left: coronal plane; Lower right: sagittal plane; Upper right: 3D reconstruction. Purple: before NAT; Yellow: after 1 cycle of NAT; Blue: after 2 cycles of NAT; Green: after 3 cycles of NAT; Red: after 5 cycles of NAT.

Click here to view

**REFERENCES**

1. Rubovszky G, Horváth Z. Recent advances in the neoadjuvant treatment of breast cancer. J Breast Cancer 2017;20:119-31.

2. Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztaí L, Chagpar AB, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg 2015;220:1063-9.
3. Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol 2011;18:3160-3. [PUBMED] [CROSSREF]

4. Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. Radiology 2017;285:358-75. [PUBMED] [CROSSREF]

5. Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol 2015;22:1416-24. [PUBMED] [CROSSREF]

6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. [PUBMED] [CROSSREF]

7. Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, et al. Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 2016;279:44-55. [PUBMED] [CROSSREF]

8. Mann RM, Cho N, Moy L. Breast MRI: state of the art. Radiology 2019;292:520-36. [PUBMED] [CROSSREF]

9. Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 2013;105:321-33. [PUBMED] [CROSSREF]

10. Ochi T, Tsunoda H, Matsuda N, Nozaki F, Suzuki K, Takei H, et al. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer. Breast Cancer 2021;28:838-47. [PUBMED] [CROSSREF]

11. Vriens BE, de Vries B, Lobbes MB, van Gastel SM, van den Berkmortel FW, Smilde TJ, et al. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. Eur J Cancer 2016;52:67-76. [PUBMED] [CROSSREF]

12. Karst I, Henley C, Gottschalk N, Floyd S, Mendelson EB. Three-dimensional automated breast US: facts and artifacts. Radiographics 2019;39:913-31. [PUBMED] [CROSSREF]

13. Berg WA, Vourtsis A. Screening breast ultrasound using handheld or automated technique in women with dense breasts. J Breast Imaging 2019;1:283-96. [CROSSREF]

14. Li JJ, Chen C, Gu Y, Di G, Wu J, Liu G, et al. The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation. PLoS One 2014;9:e88853. [PUBMED] [CROSSREF]

15. Golan O, Amitai Y, Menes T. Does change in microcalcifications with neoadjuvant treatment correlate with pathological tumour response? Clin Radiol 2016;71:458-63. [PUBMED] [CROSSREF]